{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:19Z","timestamp":1783401319277,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08201-z","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:30:30Z","timestamp":1781091030000},"page":"3967-3980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of drug use and expenditure of conventional and biological disease-modifying anti-rheumatic drugs: a study from Northwest China"],"prefix":"10.1007","volume":"45","author":[{"given":"Dan-Hong","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9153-7592","authenticated-orcid":false,"given":"Yan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"8201_CR1","doi-asserted-by":"publisher","unstructured":"Cutolo M, Smith V, Paolino S, Gotelli E (2023) Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19. Nat Rev Rheumatol 19:265\u2013287. https:\/\/doi.org\/10.1038\/s41584-023-00944-2","DOI":"10.1038\/s41584-023-00944-2"},{"key":"8201_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","volume":"82","author":"MHA Jansen","year":"2023","unstructured":"Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N, Maritsi D, van den Berg L, Berbers GAM, Bruijning P, Egert Y, Normand C, Bijl M, Foster HE, Kone-Paut I, Wouters C, Ravelli A, Elkayam O, Wulffraat NM, Heijstek MW (2023) EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis 82:35\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222574","journal-title":"Ann Rheum Dis"},{"key":"8201_CR3","doi-asserted-by":"publisher","unstructured":"Medina G, Vera-Lastra O, Peralta-Amaro AL, Jimenez-Arellano MP, Saavedra MA, Cruz-Dominguez MP, Jara LJ (2018) Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res 133:277\u2013288. https:\/\/doi.org\/10.1016\/j.phrs.2018.01.009","DOI":"10.1016\/j.phrs.2018.01.009"},{"key":"8201_CR4","doi-asserted-by":"publisher","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S (2019) Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol 234:10018\u201310031. https:\/\/doi.org\/10.1002\/jcp.27860","DOI":"10.1002\/jcp.27860"},{"key":"8201_CR5","volume-title":"Rheumatology diagnosis and treatment specifications","author":"Rheumatology Branch of the Chinese Medical Association","year":"2020","unstructured":"Rheumatology Branch of the Chinese Medical Association (2020) Rheumatology diagnosis and treatment specifications. People\u2019s Medical Publishing House, Beijing"},{"key":"8201_CR6","doi-asserted-by":"publisher","unstructured":"An Y, Liu T, He D, Wu L, Li J, Liu Y, Bi L, Zhou B, Lin C, He L, Liu X, Li X, Yang N, Zhang Z, Song H, Wei W, Liu J, Bi Y, Li Z (2017) The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol 36:35\u201343. https:\/\/doi.org\/10.1007\/s10067-016-3424-5","DOI":"10.1007\/s10067-016-3424-5"},{"key":"8201_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12913-024-10964-7","volume":"24","author":"H Li","year":"2024","unstructured":"Li H, Lin F, Wang R, Zhu C, Cao K, Chen Y, Fang G, Li J, Ding J, Li W (2024) The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China. BMC Health Serv Res 24:513. https:\/\/doi.org\/10.1186\/s12913-024-10964-7","journal-title":"BMC Health Serv Res"},{"key":"8201_CR8","doi-asserted-by":"publisher","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope JE, Takeuchi T, Hyrich KL, Winthrop KL, Aletaha D, Stamm TA, Schoones JW, Landewe RBM (2023) Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82:95\u2013106. https:\/\/doi.org\/10.1136\/ard-2022-223365","DOI":"10.1136\/ard-2022-223365"},{"key":"8201_CR9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1186\/s12889-021-11882-7","volume":"21","author":"N Wang","year":"2021","unstructured":"Wang N, Yang Y, Xu L, Mao Z, Cui D (2021) Influence of Chinese national centralized drug procurement on the price of policy-related drugs: an interrupted time series analysis. BMC Public Health 21:1883. https:\/\/doi.org\/10.1186\/s12889-021-11882-7","journal-title":"BMC Public Health"},{"key":"8201_CR10","doi-asserted-by":"publisher","unstructured":"Zhao B, Wu J (2023) Impact of China's national volume-based procurement on drug procurement price, volume, and expenditure: an interrupted time series analysis in Tianjin. Int J Health Policy Manag 12:7724. https:\/\/doi.org\/10.34172\/ijhpm.2023.7724","DOI":"10.34172\/ijhpm.2023.7724"},{"key":"8201_CR11","doi-asserted-by":"publisher","unstructured":"Qiu Y, Lyu L, Yi H, Jiang X, Zhao G, Peng B, Tan J, Jian W, Chen Y, Pan J (2025) Impact of China's national drug price negotiation policy on availability, affordability, and regional equity of negotiated drugs: a multidimensional nationwide analysis, 2018 to 2021 Value Health. https:\/\/doi.org\/10.1016\/j.jval.2025.10.002","DOI":"10.1016\/j.jval.2025.10.002"},{"key":"8201_CR12","doi-asserted-by":"publisher","unstructured":"Suo C, Li F, Yang L, Liu Q, Luo B (2024) Evaluate the effect of centralized drug procurement policy in Yunnan Province by fuzzy comprehensive evaluation. Chinese Pharmaceutical Affairs 38:768\u2013774. https:\/\/doi.org\/10.16153\/j.1002-7777.2024.07.007","DOI":"10.16153\/j.1002-7777.2024.07.007"},{"key":"8201_CR13","unstructured":"Organization WH. 57th MEETING OF THE WHO ADVISORY GROUP FOR DRUG STATISTICS METHODOLOGY. Geneva 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/international-nonproprietary-names-(inn)\/atc-ddd\/57th_atc-ddd_executive_summary.pdf. April 2025"},{"key":"8201_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2021-0002","volume":"2","author":"X Tian","year":"2018","unstructured":"Tian X, Wang Q, Li M, Zhao Y, Zhang Z, Huang C, Liu Y, Xu H, Chen Y, Wu L, Su Y, Xiao W, Zhang M, Zhao D, Sun L, Zuo X, Lei J, Li X (2018) Zeng X (2021). Chinese Guidelines for the diagnosis and treatment of rheumatoid arthritis Rheumatol Immunol Res 2:1\u201314. https:\/\/doi.org\/10.2478\/rir-2021-0002","journal-title":"Chinese Guidelines for the diagnosis and treatment of rheumatoid arthritis Rheumatol Immunol Res"},{"key":"8201_CR15","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"8201_CR16","doi-asserted-by":"publisher","unstructured":"Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev 2016:CD010227. https:\/\/doi.org\/10.1002\/14651858.CD010227.pub2","DOI":"10.1002\/14651858.CD010227.pub2"},{"key":"8201_CR17","doi-asserted-by":"publisher","unstructured":"Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 20:1\u2013610. https:\/\/doi.org\/10.3310\/hta20350","DOI":"10.3310\/hta20350"},{"key":"8201_CR18","doi-asserted-by":"publisher","unstructured":"Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R (2009) A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28:1365-1373. https:\/\/doi.org\/10.1007\/s10067-009-1233-9","DOI":"10.1007\/s10067-009-1233-9"},{"key":"8201_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1592\/phco.30.4.339","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30:339\u2013353. https:\/\/doi.org\/10.1592\/phco.30.4.339","journal-title":"Pharmacotherapy"},{"key":"8201_CR20","doi-asserted-by":"publisher","first-page":"CD012437","DOI":"10.1002\/14651858.CD012437","volume":"11","author":"JA Singh","year":"2016","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA (2016) Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev 11:CD012437. https:\/\/doi.org\/10.1002\/14651858.CD012437","journal-title":"Cochrane Database Syst Rev"},{"key":"8201_CR21","doi-asserted-by":"publisher","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2016:CD012183. https:\/\/doi.org\/10.1002\/14651858.CD012183","DOI":"10.1002\/14651858.CD012183"},{"key":"8201_CR22","doi-asserted-by":"publisher","unstructured":"Ascef BO, Almeida MO, Medeiros-Ribeiro AC, Oliveira de Andrade DC, Oliveira Junior HA, de Soarez PC (2023) Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis. JAMA Netw Open 6:e2315872. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15872","DOI":"10.1001\/jamanetworkopen.2023.15872"},{"key":"8201_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10754-006-5558-5","volume":"6","author":"YR Wang","year":"2006","unstructured":"Wang YR (2006) Price competition in the Chinese pharmaceutical market. Int J Health Care Finance Econ 6:119\u2013129. https:\/\/doi.org\/10.1007\/s10754-006-5558-5","journal-title":"Int J Health Care Finance Econ"},{"key":"8201_CR24","doi-asserted-by":"publisher","unstructured":"Mahlich J, Kamae I, Sruamsiri R (2018) Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment. Expert Rev Pharmacoecon Outcomes Res 18:339-348. https:\/\/doi.org\/10.1080\/14737167.2018.1394187","DOI":"10.1080\/14737167.2018.1394187"},{"key":"8201_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/BOR.0000000000000786","volume":"33","author":"KM D'Silva","year":"2021","unstructured":"D\u2019Silva KM, Wallace ZS (2021) COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol 33:255\u2013261. https:\/\/doi.org\/10.1097\/BOR.0000000000000786","journal-title":"Curr Opin Rheumatol"},{"key":"8201_CR26","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1007\/s10067-020-05358-z","volume":"39","author":"R Roongta","year":"2020","unstructured":"Roongta R, Ghosh A (2020) Managing rheumatoid arthritis during COVID-19. Clin Rheumatol 39:3237\u20133244. https:\/\/doi.org\/10.1007\/s10067-020-05358-z","journal-title":"Clin Rheumatol"},{"key":"8201_CR27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3899\/jrheum.220073","volume":"49","author":"J Avouac","year":"2022","unstructured":"Avouac J, Molto A, Frantz C, Wanono S, Descamps E, Fogel O, Combier A, Poiroux L, Miceli-Richard C, Allanore Y (2022) Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic. J Rheumatol 49:1269\u20131275. https:\/\/doi.org\/10.3899\/jrheum.220073","journal-title":"J Rheumatol"},{"key":"8201_CR28","doi-asserted-by":"publisher","first-page":"103409","DOI":"10.1016\/j.autrev.2023.103409","volume":"22","author":"JS Marin","year":"2023","unstructured":"Marin JS, Mazenett-Granados EA, Salazar-Uribe JC, Sarmiento M, Suarez JF, Rojas M, Munera M, Perez R, Morales C, Dominguez JI, Anaya JM (2023) Increased incidence of rheumatoid arthritis after COVID-19. Autoimmun Rev 22:103409. https:\/\/doi.org\/10.1016\/j.autrev.2023.103409","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08201-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:00Z","timestamp":1783398420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08201-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8201"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08201-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}